Sanofi(SNY) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SNY Sanofi

Watchlist

56.900
-0.890-1.54%

Close Mar 21 16:00 ET

57.500
+0.600+1.05%

Post 20:01 ET

140.38BMarket Cap23.67P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sanofi Initiated at Neutral at Goldman Sachs on Need to See Pipeline Successes
Seeking AlphaMar 21 13:31 ET
This Is What Needs to Happen for Sanofi Shares to Rally in 2025: Goldman Sachs
InvestingMar 21 09:24 ET
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
BenzingaMar 21 09:11 ET
Goldman Sachs Initiates Sanofi(SNY.US) With Hold Rating, Announces Target Price $65
Moomoo NewsMar 21 07:31 ET · Ratings
CDC Vaccine Meeting, Delayed Under RFK Jr., Is Rescheduled
Seeking AlphaMar 21 07:21 ET
Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout
Yahoo FinanceMar 21 05:28 ET

Comments

Teddy123

Mar 16 11:28

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

$Sanofi (SNY.US)$
Sanofi Leads Early Flu Vaccine Preparation as CDC Reports 40M Cases This Season

Moomoo Recap US

Dec 18, 2024 05:03

Columns Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today

The market fell Tuesday, but stepping back, the view of tech stocks looks like a mountain range that has not peaked yet- for all of December, the Nasdaq has arched upward into all-time highs. After Monday's record, the index pulled back, following a pullback for Nvidia and Broadcom, falling after Broadcom's post-earnings stock jump finally took a pause.
Just past 4 pm ET they $S&P 500 Index (.SPX.US)$ traded down 0.39%,...

10xStockPicks

Dec 16, 2024 08:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

Meltyy

Sep 25, 2024 19:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

Meltyy

Sep 10, 2024 17:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...